Loading organizations...
Enterin is a clinical-stage biopharmaceutical company developing a novel drug designed to target the gut-brain axis. The company's focus is on modifying the course of neurodegenerative disorders, including Parkinson's disease, by repairing this dysfunctional axis. Their scientific approach involves the discovery and development of synthetic derivatives of newly identified endogenous hormones.
The company was founded in 2016 by Michael Zasloff, MD, PhD, Denise Barbut, MD, FRCP, and William Kinney, PhD. This team recognized the critical connection between the gut-brain axis and the progression of neurodegenerative conditions. Their collective expertise led to the insight that developing compounds based on natural hormones could offer a therapeutic pathway for these complex diseases.
Enterin primarily serves patients suffering from neurodegenerative diseases, with an initial emphasis on Parkinson's disease. The company’s long-term vision is to establish itself as a pioneer in developing treatments that directly address and repair the dysfunctional gut-brain axis, aiming to significantly alter the trajectory of these challenging conditions and improve patient outcomes.
Enterin has raised $18.7M across 2 funding rounds.
Enterin has raised $18.7M in total across 2 funding rounds.
Enterin is a clinical‑stage biotechnology company developing small‑molecule drugs that aim to repair the gut–brain axis to treat neurodegenerative and metabolic diseases, with a lead program (ENT‑01 / kenterin) tested in Parkinson’s disease and several early‑stage programs in obesity, diabetes and other indications[4][5].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Key sources: company site and clinical/pipeline databases reporting Enterin’s lead programs, clinical activity and founding details[4][5][1].
If you’d like, I can:
Enterin has raised $18.7M in total across 2 funding rounds.
Enterin's investors include David S. Vogel, Mark Finn.
Enterin has raised $18.7M across 2 funding rounds. Most recently, it raised $6.0M Other Equity in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 3, 2022 | $6.0M Other Equity | David S. Vogel | |
| Jul 17, 2017 | $12.7M Series A | Mark Finn |